To evaluate the safety and efficacy of stereotactic radiotherapy (SRT) in metastatic RCC (mRCC) patients concurrently receiving targeted therapy or immunotherapy.
Data on mRCC patients was extracted from a retrospective international multicenter register study (TOaSTT) investigating SRT concurrent (≤30d) to TT/ICI.